Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients' tumors exhibit ...
May 16, 2022
0
46
Acral melanoma is a rare subtype that represents roughly 3% of all melanoma cases. Unlike typical melanoma that occurs on sun-exposed skin, acral melanoma develops on the nonhair bearing skin of the soles, palm and nail beds. ...
Mar 11, 2022
0
68
A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.
Mar 1, 2022
0
39
Approximately 700 people are diagnosed with diffuse large B-cell lymphoma (DLBCL) in Finland each year. It is the most common cancer that originates from lymphocytes, immune system cells. Although the disease is treated with ...
Feb 21, 2022
0
7
Mount Sinai researchers conducting clinical trials of a drug targeting a cancer gene found that it increased metastatic cancer patients' survival and was able to work within the brain, according to a study published in Clinical ...
Feb 10, 2022
0
5
A new study provides additional evidence of the efficacy of virotherapy for glioblastoma, the most deadly type of brain tumor. The research findings, published Feb. 1, 2022, in Clinical Cancer Research, indicate that an oncolytic ...
Feb 2, 2022
0
19
(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab versus sunitinib have longer treatment-free survival (TFS), according to a study published online ...
Dec 3, 2021
0
9
Researchers at Mass Eye and Ear and Mass General Hospital have developed a blood test, or liquid biopsy, for head and neck cancer associated with the human papilloma virus (HPV) that was shown in a new study to be more accurate, ...
Dec 2, 2021
0
2
Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain ...
Nov 15, 2021
0
12
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients ...
Nov 10, 2021
0
2
